Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) were down 1.6% during trading on Tuesday. The stock traded as low as $28.35 and last traded at $28.4050. Approximately 35,221,329 shares changed hands during trading, a decline of 11% from the average session volume of 39,712,441 shares. The stock had previously closed at $28.86.
More Pfizer News
Investors following PFE have been watching these news items:
- Neutral Sentiment: Pfizer updated information on an ongoing real-world safety study of Xeljanz XR. The available report does not describe new safety findings, so the update’s implications for the drug or company are unclear. Read More.
- Negative Sentiment: A comparison with Johnson & Johnson describes Pfizer’s revenue as more volatile across recent quarters, while J&J showed steadier growth. That contrast may weigh on confidence in the consistency of Pfizer’s business. Read More.
- Negative Sentiment: Options activity was characterized as moderately bearish, suggesting some traders are positioning cautiously around PFE. Read More.
Analysts Set New Price Targets
A number of research analysts have weighed in on PFE shares. DZ Bank lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, November 6th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. Scotiabank raised their price target on Pfizer from $33.00 to $35.00 and gave the company a “sector outperform” rating in a research report on Wednesday, November 4th. HSBC lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. Finally, Guggenheim boosted their price objective on Pfizer from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Six investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $30.32.
Pfizer Stock Performance
The firm’s 50 day moving average price is $28.81 and its 200-day moving average price is $27.00. The firm has a market cap of $161.90 billion, a price-to-earnings ratio of 40.58, a P/E/G ratio of 1.89 and a beta of 0.31. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.10.
Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The firm had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the prior year, the company earned $0.87 EPS. The business’s quarterly revenue was down .4% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 3.04 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer’s dividend payout ratio is currently 245.71%.
Institutional Investors Weigh In On Pfizer
A number of institutional investors have recently added to or reduced their stakes in the company. Quantitative Investment Management LLC acquired a new stake in Pfizer during the third quarter worth $312,000. Aspen Grove Capital LLC raised its stake in shares of Pfizer by 1.3% in the 3rd quarter. Aspen Grove Capital LLC now owns 64,158 shares of the biopharmaceutical company’s stock valued at $1,830,000 after buying an additional 807 shares in the last quarter. Greenwich Wealth Management LLC raised its stake in shares of Pfizer by 5.2% in the 3rd quarter. Greenwich Wealth Management LLC now owns 147,604 shares of the biopharmaceutical company’s stock valued at $4,210,000 after buying an additional 7,307 shares in the last quarter. WCG Wealth Advisors LLC lifted its holdings in shares of Pfizer by 4.5% during the 3rd quarter. WCG Wealth Advisors LLC now owns 83,107 shares of the biopharmaceutical company’s stock worth $2,370,000 after acquiring an additional 3,595 shares during the period. Finally, Worldquant Millennium Advisors LLC lifted its holdings in shares of Pfizer by 810.2% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 2,357,652 shares of the biopharmaceutical company’s stock worth $67,240,000 after acquiring an additional 2,098,613 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Featured Articles
- Five stocks we like better than Pfizer
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
